Nivolumab plus cabozantinib (NIVO plus CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER Meeting Abstract
| Authors: | Motzer, R. J.; Choueiri, T. K.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Maruzzo, M.; Shah, A. Y.; Suarez, C.; Barrios, C. H.; Richardet, M. E.; Porta, C.; Goh, J. C.; Tomita, Y.; Bedke, J.; Zhang, J.; Simsek, B.; Scheffold, C.; Gupta, S.; Apolo, A. B. |
| Abstract Title: | Nivolumab plus cabozantinib (NIVO plus CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER |
| Meeting Title: | 2021 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2021 Feb 11-13 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-02-20 |
| Language: | English |
| ACCESSION: | WOS:000636801500323 |
| DOI: | 10.1200/JCO.2021.39.6_suppl.308 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 308 -- Source: Wos |
